Skip to main content
GNI Group Ltd. logo

GNI Group Ltd. — Investor Relations & Filings

Ticker · 2160 ISIN · JP3386370005 LEI · 5299005KSTCN0WVJMQ52 T Manufacturing
Open in API
Filings indexed 100 across all filing types
Latest filing 2026-06-05 Investor Presentation
Country JP Japan
Listing T 2160

About GNI Group Ltd.

https://www.gnipharma.com/

GNI Group Ltd. is a vertically integrated, multinational biopharmaceutical company engaged in the full spectrum of drug development, from research and clinical trials to manufacturing, sales, and marketing. The company's portfolio includes pharmaceutical drugs, traditional Chinese medicines, and medical devices. Its research and development efforts are primarily focused on creating therapies for diseases such as cancer and inflammation, with a particular emphasis on conditions prevalent in Asian populations. The group utilizes genetic information and analysis technology to advance its drug discovery programs.

Recent filings

Filing Released Lang Actions
あゆみ製薬ホールディングス株式会社の完全子会社化について
Investor Presentation Classification · 87% confidence The document is a lengthy slide deck with agenda, highlights, strategic rationale, financial overviews, and pipeline details related to GNI Group’s acquisition of Ayumi Pharmaceutical Holdings. It is structured as a presentation (with slide titles, images, and bullet points) aimed at investors and stakeholders, rather than an official regulatory filing or standalone earnings release. This matches the definition of an Investor Presentation (IP).
2026-06-05 Japanese
Transformational Acquisition of Ayumi Pharmaceutical Holdings
Investor Presentation Classification · 95% confidence The document is a slide deck with an agenda, transaction highlights, strategic rationale, deal structure diagrams, financial tables, and company profiles, clearly formatted as a presentation for investors outlining the acquisition of Ayumi Pharmaceutical by GNI Group. There is no regulatory form, proxy statement, or call transcript language, nor does it merely announce a forthcoming report. It is a full investor presentation. Therefore, it should be classified as Investor Presentation (IP).
2026-06-05 English
Notice Concerning Acquisition of All Shares of AYUMI Pharmaceutical Holdings KK(Conversion into a Wholly Owned Subsidiary) and Issuance of New Shares
M&A Activity Classification · 88% confidence The document is a formal Japanese regulatory announcement titled “Notice Concerning Acquisition of All Shares… and Issuance of New Shares by Third-Party Allotment.” It provides detailed information on the share acquisition of AYUMI Pharmaceutical Holdings (conversion into a wholly owned subsidiary) and the accompanying third-party allotment. This constitutes an M&A transaction announcement rather than a pure capital markets update or financial report. It does not correspond to US SEC merger proxy forms or tender-offer filings (MA), but is a general M&A announcement. Therefore, it best fits the M&A Activity category (TAR).
2026-06-05 English
Notice Concerning Expected Change in Major Shareholder and Largest Major Shareholder
Major Shareholding Notification Classification · 95% confidence The document is a formal notice from GNI Group Ltd. announcing an expected change in its major shareholder and largest major shareholder due to a third-party allotment of new shares. There is no financial report or certification content; it is purely a disclosure of changes in significant share ownership thresholds. This aligns precisely with the Major Shareholding Notification category.
2026-06-05 English
主要株主及び主要株主である筆頭株主の異動に関するお知らせ
Major Shareholding Notification Classification · 92% confidence The document is a Japanese disclosure titled “主要株主及び主要株主である筆頭株主の異動に関するお知らせ,” detailing the expected change in the company’s major shareholder – BCP Asia AYM Holding (Cayman) L.P. – and providing shareholding percentages before and after the allotment. This aligns exactly with a Major Shareholding Notification (changes in significant share ownership levels).
2026-06-05 Japanese
あゆみ製薬ホールディングス株式会社の全株式の取得（完全子会社化）及び 第三者割当による新株式の発行（現物出資）に関するお知らせ
M&A Activity Classification · 85% confidence The document is a Japanese stock exchange notice explaining the board resolution to acquire all outstanding shares of Ayumi Pharmaceutical Holdings and make it a wholly owned subsidiary, together with a third-party allotment of new shares (capital change) to the sellers as in-kind consideration. This is a definitive M&A transaction announcement (takeover of a subsidiary) and related equity issuance. Under the filing definitions, this is best classified as M&A Activity (Code: TAR).
2026-06-05 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.